|
Country: Belgium
City: Leuven
IHTC:
University of Leuven, Centre for Molecular and Vascular Biology
Campus Gasthuisberg, O & N, Herestraat 49, B-3000, Leuven, Belgium
Tel.: 32 16 343 491; 32 16 346 018
Fax: 32 16 345 990; 32 16 343 493
Email: kathelijne.peerlinck@med.kuleuven.ac.be
Website: http://www.med.kuleuven.ac.be
Director: Kathelijne Peerlinck
Responsible for training: Kathelijne Peerlinck; C Van Geet for pediatrics; J. Arnout for laboratory training; F. Vinckier and D. Declercq for dental program.
Year of IHTC designation: 1972
Areas of specialty: General hemophilia care; pediatrics; dental; laboratory diagnosis (not genetics)
DESCRIPTION OF TRAINING PROGRAM
Clinical activities: The Haemophilia Treatment Centre is part of the Department of Internal Medicine. The Centre assures the regular follow-up of 600 patients with hemophilia and other bleeding disorders.
Laboratory activities/research: Our routine coagulation laboratory performs all tests necessary to diagnose patients with bleeding (and thrombotic) disorders. Our research laboratory is involved in research manly on factor VIII inhibitors, platelet disorders and lupus anticoagulant.
Multidisciplinary activities/research: Once weekly, a multidisciplinary consultation (including orthopedics, paediatrics, physical therapy and psych-pedagogic support as needed) is organized. Support is provided for patients on home treatment. Peri- and postoperative treatment is provided for general surgical and orghopedic operations. A specialized nurse is attached to the centre, and is responsible for instruction of auto transfusion.
Additional information: It trains 1-2 fellows annually
DESCRIPTION OF IHTC FACILITIES
Location: The centre is located centrally in Leuven.
Climate: Moderate
Accommodation (residence, meals, etc...):
Transportation:
Language: Dutch, English and French
Financial assistance: Dependent on WFH funds.
Cost of living (per week):
Communications tools for trainees:
Other local support provided for trainees:
RELEVANT PUBLICATIONS BY IHTC STAFF
Peerlinck K., Rosendaal F.R., Vermylen J. Incidence of inhibitors development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 81: 3332-3335, 1993.
Gilles J.G., Desqueper B., Lenk H., Vermylen J., Sain-Remy J-M. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J. Clin. Invest. 97: 1382-1388, 1996.
Peerlinck K., Arnout J., De Giambattista M., Gilles J.G., Lamb R., Jacquemin M., Saint-Remy J.M., Vermylen J. Factor VIII inhibitiors with a double virus-activated plasma derived factor VIII concentrate. Thromb. Haemost. 77: 80-86, 1997.
Peerlinck K., Jacquemin M.G., Arnout J., Hoylaerts M.F., Gilles J.G.G., Lavendhomme R., Johnson K.M., Freson K., Scandella D., Saint-Remy J.M., Vermylen J. Antifactor VIII antibody inhibiting allogenic but not antologous factor VIII in patients with mild hemophilia A. Blood 93: 2267-2273, 1999. |
